CD80
T-lymphocyte activation antigen CD80
As of the edition of 20 October 2026, CD80 (T-lymphocyte activation antigen CD80, UniProt P33681) has 3 drugs tested at it and 1 company on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P33681
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 6
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Blood and lymph; Cancer; Pregnancy and women's health; Urinary and reproductive; Nervous system
- Registered trials of its drugs
- 232
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Abatacept | Marketed | Phase 4 | Ends 2028 |
| Belatacept | Marketed | Phase 4 | Ended 2023 |
| Galiximab | Went quiet | Phase 3 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Total on the list | 1 |
| Company | Route |
|---|---|
| Biogen | Route A |
The other 0 companies at CD80
In the product1 company in all; 0 are not named here, and no score is.
See the 1 companies at CD80, ranked, with the facts behind eachRequest access. Nothing is shown until you do.